The Coronavirus Disease of 2019: Prevention, Management and Treatment Strategies

N. Egbe, Chukwu C. Onyedikachi, Ashiru M. Dantata, Surajo Jamaliddeen, A. Awanye
{"title":"The Coronavirus Disease of 2019: Prevention, Management and Treatment Strategies","authors":"N. Egbe, Chukwu C. Onyedikachi, Ashiru M. Dantata, Surajo Jamaliddeen, A. Awanye","doi":"10.9734/JABB/2021/V24I130193","DOIUrl":null,"url":null,"abstract":"The recent COVID-19 pandemic caused by the novel coronavirus (SARS-CoV2) has taken the world by surprise since its outbreak in 2019, and as on February 2021, the world had experienced a total of 107,643,141 (one hundred and seven million, six hundred and forty-three thousand, one hundred and forty-one) confirmed infection cases and 2,358,244 (two million, three hundred and fifty-eight thousand, two hundred and forty-four) deaths world-wide. This virus, although less lethal than the previous human coronaviruses (SARS-CoV and MERS-CoV), is reported highly infectious and mutable. This has led to a concerted effort by numerous governments and private organisations to try and halt the spread of the virus through the development of highly effective therapeutic drugs or prophylactic therapy. There are various drugs, vaccines and other forms of Review Article Egbe et al.; JABB, 24(1): 12-24, 2021; Article no.JABB.65162 13 therapies currently being developed all over the world, with some at various clinical trial stages, with only one (Remdesivir) being fully approved treatment of the COVID-19 disease. The latest breakthrough with Dexamethasone has currently revealed the efficacy of the drug in treating critically ill and even mechanically ventilated COVID-19 patients, and this has led to the approval of the drug by the United Kingdom and World Health Organization (WHO). The recent development of a protective SARS-CoV-2 vaccine has created hope for life and restoration of normalcy.","PeriodicalId":15023,"journal":{"name":"Journal of Advances in Biology & Biotechnology","volume":"20 1","pages":"12-24"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Advances in Biology & Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/JABB/2021/V24I130193","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The recent COVID-19 pandemic caused by the novel coronavirus (SARS-CoV2) has taken the world by surprise since its outbreak in 2019, and as on February 2021, the world had experienced a total of 107,643,141 (one hundred and seven million, six hundred and forty-three thousand, one hundred and forty-one) confirmed infection cases and 2,358,244 (two million, three hundred and fifty-eight thousand, two hundred and forty-four) deaths world-wide. This virus, although less lethal than the previous human coronaviruses (SARS-CoV and MERS-CoV), is reported highly infectious and mutable. This has led to a concerted effort by numerous governments and private organisations to try and halt the spread of the virus through the development of highly effective therapeutic drugs or prophylactic therapy. There are various drugs, vaccines and other forms of Review Article Egbe et al.; JABB, 24(1): 12-24, 2021; Article no.JABB.65162 13 therapies currently being developed all over the world, with some at various clinical trial stages, with only one (Remdesivir) being fully approved treatment of the COVID-19 disease. The latest breakthrough with Dexamethasone has currently revealed the efficacy of the drug in treating critically ill and even mechanically ventilated COVID-19 patients, and this has led to the approval of the drug by the United Kingdom and World Health Organization (WHO). The recent development of a protective SARS-CoV-2 vaccine has created hope for life and restoration of normalcy.
2019年冠状病毒病:预防、管理和治疗策略
最近由新型冠状病毒(SARS-CoV2)引起的COVID-19大流行自2019年爆发以来震惊了世界,截至2021年2月,全世界共发生107,643,141例(一亿七千六十四万三千一百四十一例)确诊感染病例和2,358,244例(二百三十五万八千二百四十四例)死亡。这种病毒虽然不如以前的人类冠状病毒(SARS-CoV和MERS-CoV)致命,但据报道具有高度传染性和易变性。这导致许多政府和私人组织共同努力,试图通过开发高效的治疗药物或预防性治疗来阻止病毒的传播。有各种药物、疫苗和其他形式的审查文章Egbe等;Jabb, 24(1): 12- 24,2021;文章no.JABB。65162全球目前正在开发13种治疗方法,其中一些处于不同的临床试验阶段,只有一种(Remdesivir)被完全批准用于治疗COVID-19疾病。目前,地塞米松的最新突破揭示了该药对危重患者甚至机械通气患者的疗效,这使得该药获得了英国和世界卫生组织(世卫组织)的批准。最近研制出的保护性SARS-CoV-2疫苗为生命和恢复正常带来了希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信